Ｄｕｒｉｎｇ ｔｈｅ ｐａｓｔ ５４ ｍｏｎｔｈｓ ａ ｔｏｔａｌ ｏｆ ２４ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｓｅｃｏｎｄａｒｙ ｈｅｐａｔｉｃ ｃａｒｃｉｎｏｍａ ｈａｖｅ ｂｅｅｎ ｔｒｅａｔｅｄ ｂｙ ｒｅｓｅｃｔｉｏｎ ｏｆ ｈｅｐａｔｉｃ ｍｅｔａｓｔａｓｉｓ ａｎｄ ｐｏｓｔｏｐｅｒａｔｉｏｎ ｐｅｒｃｕｔａｎｅｏｕｓ ｉｎｔｒａｈｅｐａｔｏｐｏｒｔａｌ ｃｈｅｍｏｔｈｅｒａｐｙ（ＰＨＰＣ） ｕｎｄｅｒ ｕｌｔｒａｓｏｕｎｄ ｇｕｉｄａｎｃｅ Ａ ｆｏｌｌｏｗｕｐ ｆｒｏｍ ｆｉｖｅ ｍｏｎｔｈｓ ｔｏ ｆｏｕｒ ｙｅａｒｓ ｓｈｏｗｓ ｔｈａｔ ２１ ｐａｔｉｅｎｔｓ ｈａｖｅ ｓｕｒｖｉｖｄｅ ｆｏｒ ５ ｔｏ ４８ ｍｏｎｔｈｓ ｅｘｃｅｐｔ ３ ｅｘｔｒｅｍｅｌｙ ａｄｖａｎｃｅｄ ｃａｓｅｓ． Ｔｈｅ ａｕｔｈｏｒｓ ｓｕｇｇｅｓｔ ｔｈａｔ ａ ｃｏｍｂｉｎｅｄ ｔｈｅｒａｐｅｕｔｉｃ ｍｅｔｈｏｄ ｆｏｒ ｔｒｅａｔｉｎｇ ｓｅｃｏｎｄａｒｙ ｈｅｐａｔｉｃ ｃａｒｃｉｎｏｍａ ｉｓ ｍｏｒｅ ｅｆｆｅｃｔｉｖｅ ｔｈａｎ ｅｉｔｈｅｒ ｓｉｍｐｌｅ ｈｅｐａｔｅｃｔｏｍｙ ｏｒ ｃｈｅｍｏｔｈｅｒａｐｙ．
During the past 42 months, a total of 53 patients with primary hepatic carcinoma (PHC) had been treated by fine needle percutanous ethanol intratumor infiltration (group P) and ethanol infiltration combined with intrahepatoportal chemotherapy around carcinoma, using adriamycin (group PA) or using adriamycin, carboplytin mitomycin and 5-Fu (group PC) for two courses. Result showed that 16cases were complete remission and 21 cases were part remission. The overall response rate was 69.8%, with a median survival duration of 10.1 months. After clinical contrast among three groups, the response rate in PA group exceeded P and PC group and adverse reactions was lower than PC group. The authors belive that this method might be a remedial measure for patients who are unsuitable for major surgery.
Objective To study the efficiency of percutaneous acetic acid injection (PAI) or percutaneous ethanol injection (PEI) in the treatment of primary hepatic carcinoma (PHC). Methods Seventeen and 24 patients with PHC were treated, respectively by PAI or by PEI in our hospital. According to hepatic function test, soluble intereukin-2 receptor (sIL-2R), AFP, biopsy and size of tumor, the evaluation was made.Results Effective rate was 88.2% in PAI group and 87.5% in PEI group, respectively. There was no obvious influence to sIL-2R in serum in the two groups (Ｐ＞0.05). Obvious differences in impairment of hepatic functions between PAI and PEI groups were found (Ｐ＜0.01), it also showed that smaller amounts of acetic acid and less puncture frequency were required for the treatment than that of ethanol. Conclusion PAI is superior to PEI in the treatment of those patients who are complicated with cirrhosis or other vital disease.
Objective To investigate the variety of telomerase activity in the course of liver cancer development, and the possibility of using telomerase as a marker of HCC. Methods Human liver specimens, comprising 22 HCC and adjacent peritumoral tissues, 12 liver cirrhosistissues, 6 nodulat regenerative hyperplasia (NRH) tissues and 10 normal liver tissues, were examined for telomerase activity by TRAP assay based on PCR. Results Twenty of 22 HCC and 14 of 22 adjacent tissue specimens were positive for telomerase activity with a positive rate of 90.9% and 63.6% respectively. Ten of 12 liver cirrhosis tissues were positive with a positive rate of 83.3%. 5 of 6 NRH were positive with a positive rate of 83.3%. Telomerase activity was negative in 10 normal liver tissues. Conclusion Telomerase may occur in the progress of hepatocarcinogenesis. Telomerase can be used as a tumor marker of HCC.